Raf Van Campenhout

Dr. Raf Van Campenhout

PhD candidate
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RCRaf Van Campenhout
Raf Van Campenhout
AGAna Rita Gomes
Ana Rita Gomes
Timo De GroofTimo De Groof
Timo De Groof
Serge MuyldermansSerge Muyldermans
Serge Muyldermans
Nick DevoogdtNick Devoogdt
Nick Devoogdt
Mathieu VinkenMathieu Vinken
Mathieu Vinken
Gap junctions and connexin hemichannels mediate intercellular and extracellular communication, respectively. While gap junctions are seen as the “good guys” by controlling homeostasis, connexin hemichannels are considered as the “bad guys”, as their activation is associated with the onset and dissemination of disease. Open connexin hemichannels indeed mediate the transport of messengers between the cytosol and extracellular environment and, by doing so, fuel inflammation and cell death in a plethora of diseases. The present mini-review discusses the mechanisms involved in the activation of connexin hemichannels during pathology.

Verified
Journal Article
Open access
PDF file
ATAndrés Tabernila
Andrés Tabernila
BRBruna dos Santos Rodrigues
Bruna dos Santos Rodrigues
APAlanah Pieters
Alanah Pieters
ACAnne Caufriez
Anne Caufriez
KLKaat Leroy
Kaat Leroy
Mathieu VinkenMathieu Vinken
Mathieu Vinken
The liver is among the most frequently targeted organs by noxious chemicals of diverse nature. Liver toxicity testing using laboratory animals not only raises serious ethical questions, but is also rather poorly predictive of human safety towards chemicals. Increasing attention is, therefore, being paid to the development of non-animal and human-based testing schemes, which rely to a great extent on in vitro methodology. The present paper proposes a rationalized tiered in vitro testing strategy to detect liver toxicity triggered by chemicals, in which the first tier is focused on assessing general cytotoxicity, while the second tier is aimed at identifying liver-specific toxicity as such. A state-of-the-art overview is provided of the most commonly used in vitro assays that can be used in both tiers. Advantages and disadvantages of each assay as well as overall practical considerations are discussed.

23 August 2020 in Biomolecules
Verified
Journal Article
Open access
PDF file
OROlga Martyna Rusiecka
Olga Martyna Rusiecka
JMJade Montgomery
Jade Montgomery
Sandrine MorelSandrine Morel
Sandrine Morel
DBDaniela Batista-Almeida
Daniela Batista-Almeida
RCRaf Van Campenhout
Raf Van Campenhout
BKBrenda Kwak
Brenda Kwak
Since the mid-20th century, ischemic heart disease has been the world’s leading cause of death. Developing effective clinical cardioprotection strategies would make a significant impact in improving both quality of life and longevity in the worldwide population. Both ex vivo and in vivo animal models of cardiac ischemia/reperfusion (I/R) injury are robustly used in research. Connexin43 (Cx43), the predominant gap junction channel-forming protein in cardiomyocytes, has emerged as a cardioprotective target. Cx43 posttranslational modifications as well as cellular distribution are altered during cardiac reperfusion injury, inducing phosphorylation states and localization detrimental to maintaining intercellular communication and cardiac conduction. Pre- (before ischemia) and post- (after ischemia but before reperfusion) conditioning can abrogate this injury process, preserving Cx43 and reducing cell death. Pre-/post-conditioning has been shown to largely rely on the presence of Cx43, including mitochondrial Cx43, which is implicated to play a major role in pre-conditioning. Posttranslational modifications of Cx43 after injury alter the protein interactome, inducing negative protein cascades and altering protein trafficking, which then causes further damage post-I/R injury. Recently, several peptides based on the Cx43 sequence have been found to successfully diminish cardiac injury in pre-clinical studies.

1 April 2019 in Talanta
Verified
Journal Article
Closed access
EDEric Deconinck
Eric Deconinck
RCRaf Van Campenhout
Raf Van Campenhout
CAC. Aouadi
C. Aouadi
MCM. Canfyn
M. Canfyn
JBJ.L. Bothy
J.L. Bothy
PCP. Courselle
P. Courselle

1 January 2019
Verified
Book Chapter
Closed access
VVVânia Vilas-Boas
Vânia Vilas-Boas
ACAxelle Cooreman
Axelle Cooreman
EGEva Gijbels
Eva Gijbels
RCRaf Van Campenhout
Raf Van Campenhout
EGEmma Gustafson
Emma Gustafson
Mathieu VinkenMathieu Vinken
Mathieu Vinken

23 February 2019 in Hepatology
Verified
Journal Article
Closed access
PDF file
ACAxelle Cooreman
Axelle Cooreman
RCRaf Van Campenhout
Raf Van Campenhout
SBSteven Ballet
Steven Ballet
PAPieter Annaert
Pieter Annaert
BBBert Van Den Bossche
Bert Van Den Bossche
Mathieu VinkenMathieu Vinken
Mathieu Vinken